Operation Web Tryp

Last updated

Operation Web Tryp was a United States Drug Enforcement Administration operation that ended on July 21, 2004 with the arrests of 10 persons. Its purpose was to investigate web sites suspected of distribution of unscheduled, unregulated tryptamines and phenethylamines of questionable legality. This trade in "grey market" drugs, which were not explicitly illegal but potentially prosecutable as drug analogs, became known as the "research chemical" trade; a euphemism to suggest that the chemicals were being sold for industrial or academic research rather than human consumption. [1]

Five websites were involved in Operation Web Tryp. [2] One of these websites, pondman.nu, was allegedly taking in U.S. $20,000 per week and grossed $700,000 before being shut down. Another, racresearch.com, reportedly grossed $500,000 in 14 months. [3]

In 2005, a court ruled that AMT sold by pondman.nu caused the April 2002 death of an 18-year-old male in upstate New York and the site's owner was sentenced to 410 years in prison. [1] The DEA also alleged a product sold by americanchemicalsupply.com caused the death of a 22-year-old Louisiana man. Fourteen other non-fatal overdose incidents requiring hospitalization were also cited by the DEA. [3]

In December 2004, using credit card information provided by the DEA, British police arrested 22 UK residents who had purchased 2C-I through the seized web sites (Operation Ismene). [1] [4] No one was jailed and most were released without charge. [1] No customers in the United States were known to be arrested. [3]

Legality

Although these chemicals were not yet scheduled, a long shadow was cast on their legality by the 1986 Federal Analog Act. This Act and the United States v. Forbes Colorado federal district court case stipulated that the burden of proof, in regards for the intention for human consumption, was on the government if any prosecution under the Federal Analog Act was to occur. Additionally, legal ambiguities regarding the legality of certain analogs of scheduled substances had been established in the aforementioned court case (In particular, the similarities of AET and DMT were debated).

Related Research Articles

<span class="mw-page-title-main">Controlled Substances Act</span> United States drug-regulating law

The Controlled Substances Act (CSA) is the statute establishing federal U.S. drug policy under which the manufacture, importation, possession, use, and distribution of certain substances is regulated. It was passed by the 91st United States Congress as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and signed into law by President Richard Nixon. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs.

<span class="mw-page-title-main">Drug Enforcement Administration</span> United States federal law enforcement agency

The Drug Enforcement Administration (DEA) is a United States federal law enforcement agency under the U.S. Department of Justice tasked with combating illicit drug trafficking and distribution within the U.S. It is the lead agency for domestic enforcement of the Controlled Substances Act, sharing concurrent jurisdiction with the Federal Bureau of Investigation, the U.S. Immigration and Customs Enforcement, and U.S. Customs and Border Protection. However, the DEA has sole responsibility for coordinating and pursuing U.S. drug investigations both domestically and internationally.

<span class="mw-page-title-main">Methaqualone</span> Sedative–hypnotic drug withdrawn due to recreational abuse

Methaqualone is a hypnotic sedative. It was sold under the brand names Quaalude and Sopor among others, which contained 300 mg of methaqualone, and sold as a combination drug under the brand name Mandrax, which contained 250 mg methaqualone and 25 mg diphenhydramine within the same tablet, mostly in Europe. Commercial production of methaqualone was halted in the mid-1980s due to widespread abuse and addictiveness. It is a member of the quinazolinone class.

<span class="mw-page-title-main">2C-T-7</span> Psychedelic phenthylamine drug

2C-T-7 is a psychedelic phenethylamine of the 2C family. In his book PiHKAL: A Chemical Love Story, Alexander Shulgin lists the dosage range as 10–30 mg. 2C-T-7 is generally taken orally, and produces psychedelic and entactogenic effects that last 8 to 15 hours. Up until Operation Web Tryp and three deaths, two of which involved the use of other drugs in addition to 2C-T-7, and one which involved an excessive insufflated dose, 2C-T-7 was sold commercially in Dutch and Japanese smartshops and online. It is known on the streets as Blue Mystic or 7th Heaven. There has been little real research done on this chemical other than Shulgin's comments in PiHKAL and a few small animal studies mostly aimed at detecting metabolites.

<span class="mw-page-title-main">Clandestine chemistry</span> Illegal preparation of chemicals

Clandestine chemistry is chemistry carried out in secret, and particularly in illegal drug laboratories. Larger labs are usually run by gangs or organized crime intending to produce for distribution on the black market. Smaller labs can be run by individual chemists working clandestinely in order to synthesize smaller amounts of controlled substances or simply out of a hobbyist interest in chemistry, often because of the difficulty in ascertaining the purity of other, illegally synthesized drugs obtained on the black market. The term clandestine lab is generally used in any situation involving the production of illicit compounds, regardless of whether the facilities being used qualify as a true laboratory.

<span class="mw-page-title-main">2C-T-21</span> Psychedelic phenethylamine drug

2C-T-21 is a psychedelic phenethylamine of the 2C family sometimes used as an entheogen. It was first synthesized by Alexander Shulgin.

<span class="mw-page-title-main">5-MeO-aMT</span> Chemical compound

5-MeO-αMT or 5-methoxy-α-methyltryptamine, α,O-Dimethylserotonin (Alpha-O) is a potent psychedelic tryptamine. It is soluble in ethanol.

<span class="mw-page-title-main">Federal Analogue Act</span> Section of the United States Controlled Substances Act

The Federal Analogue Act, 21 U.S.C. § 813, is a section of the United States Controlled Substances Act passed in 1986 which allows any chemical "substantially similar" to a controlled substance listed in Schedule I or II to be treated as if it were listed in Schedule I, but only if intended for human consumption. These similar substances are often called designer drugs. The law's broad reach has been used to successfully prosecute possession of chemicals openly sold as dietary supplements and naturally contained in foods. The law's constitutionality has been questioned by now Supreme Court Justice Neil Gorsuch on the basis of Vagueness doctrine.

A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union, Australia, and New Zealand, as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids.

<span class="mw-page-title-main">DiPT</span> Chemical compound

Diisopropyltryptamine is a psychedelic hallucinogenic drug of the tryptamine family that has a unique effect. While the majority of hallucinogens affect the visual sense, DiPT is primarily aural.

<span class="mw-page-title-main">Removal of cannabis from Schedule I of the Controlled Substances Act</span> Proposed changes to the legal status of cannabis in U.S. federal law

In the United States, the removal of cannabis from Schedule I of the Controlled Substances Act, the category reserved for drugs that have "no currently accepted medical use", is a proposed legal and administrative change in cannabis-related law at the federal level. After being proposed repeatedly since 1972, in 2024, the U.S. Department of Justice announced it was initiating rulemaking to reschedule cannabis to Schedule III of the Controlled Substances Act.

A structural analog, also known as a chemical analog or simply an analog, is a compound having a structure similar to that of another compound, but differing from it in respect to a certain component.

<span class="mw-page-title-main">2C-T</span> Chemical compound

2C-T is a psychedelic and hallucinogenic drug of the 2C family. It is used by some as an entheogen. It has structural and pharmacodynamic properties similar to the drugs mescaline and 2C-T-2.

<span class="mw-page-title-main">2C-TFM</span> Psychedelic phenethylamine drug

2C-TFM is a psychedelic phenethylamine of the 2C family. It was first synthesized in the laboratory of David E. Nichols. It has also been called 2C-CF3, a name derived from the Para-trifluoromethyl group it contains.

<span class="mw-page-title-main">DESOXY</span> Chemical compound

4-Desoxymescaline, or 4-methyl-3,5-dimethoxyphenethylamine, is a mescaline analogue related to other psychedelic phenethylamines. It is commonly referred to as DESOXY. DESOXY was discovered by Alexander Shulgin and published in his book PiHKAL.

<span class="mw-page-title-main">Drug policy of California</span> Overview of the drug policy of the U.S. state of California

Drug policy of California refers to the policy on various classes and kinds of drugs in the U.S. state of California. Cannabis possession has been legalized with the Adult Use of Marijuana Act, passed in November 2016, with recreational sales starting January of the next year. With respect to many controlled substances, terms such as illegal and prohibited do not include their authorized possession or sale as laid out by applicable laws.

The Colima Cartel was a Mexican drug trafficking and methamphetamine producing cartel operating in Guadalajara, Jalisco. It was founded and led by José de Jesús Amezcua Contreras and supported by his brothers Adán and Luis.

<span class="mw-page-title-main">Cannabis in the United States</span>

The use, sale, and possession of cannabis containing over 0.3% THC by dry weight in the United States, despite laws in many states permitting it under various circumstances, is illegal under federal law. As a Schedule I drug under the federal Controlled Substances Act (CSA) of 1970, cannabis containing over 0.3% THC by dry weight is considered to have "no accepted medical use" and a high potential for abuse and physical or psychological dependence. Cannabis use is illegal for any reason, with the exception of FDA-approved research programs. However, individual states have enacted legislation permitting exemptions for various uses, including medical, industrial, and recreational use.

<span class="mw-page-title-main">Drugs in the United States</span>

In the United States, the Federal Food, Drug, and Cosmetic Act defined the word "drug" as an "article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals" and those "(other than food) intended to affect the structure or any function of the body of man or other animals." Consistent with that definition, the U.S. separately defines narcotic drugs and controlled substances, which may include non-drugs, and explicitly excludes tobacco, caffeine and alcoholic beverages.

Operation DRYER is a joint operation between the Spanish Civil Guard, Austrian police, and Europol working to shut down labs and organizations which produce designer drugs. Authorities seized over 4.5 million euros' worth of cryptocurrency, as well as 788,606 doses of LSD; these are the largest seizures of cryptocurrency and LSD in European history. The operation was revealed to the public on June 28, 2018.

References

  1. 1 2 3 4 Mike Power (2 May 2013). "The rise and fall of the research chemical scene". Drugs 2.0: The Web Revolution That's Changing How the World Gets High. Granta Publications. pp. 92–95. ISBN   978-1-84627-461-9.
  2. "DEA announces arrests of website operators selling illegal designer drugs". Drug Enforcement Administration. 2004-07-22. Archived from the original on 2005-12-25.
  3. 1 2 3 David McCandless, "Bad Trip for Online Drug Peddlers", Wired magazine, July 6, 2005
  4. "Arrests in online drugs operation". BBC News . 20 December 2004.